

**Editor**

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 8.727

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2013 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 631** New targets for disease modifying osteoarthritis drugs: chondrogenesis and Runx1
F J Blanco, C Ruiz-Romero

Viewpoint

- 635** Gout treatment: should we aim for rapid crystal dissolution?
E Pascual, M Andrés, P Vela

Review

- 638** A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia
P V Chowalloor, H I Keen

Clinical and epidemiological research

- 646** Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study
T A Hoeven, M Kavousi, S Clockaerts, H J M Kerkhof, J B van Meurs, O Franco, A Hofman, P Bindels, J Witteman, S Bierma-Zeinstra
- 652** Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile
K Lundberg, C Bengtsson, N Kharlamova, E Reed, X Jiang, H Kallberg, I Pollak-Dorocic, L Israelsson, C Kessel, L Padyukov, R Holmdahl, L Alfredsson, L Klareskog
- 659** Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study
C C Mok, L Y Ho, L S Fong, C H To
- 665** The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound
M Dougados, V Devauchelle-Pensec, J F Ferlet, S Jousse-Joulin, M-A D'Agostino, M Backhaus, J Bentin, G Chalès, I Chary-Valckenaere, P Conaghan, R J Wakefield, F Etcheperre, P Gaudin, W Grassi, D van der Heijde, X Mariette, E Naredo, M Szkudlarek
- 672** Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish register, 2000–8
V M Rantalaaho, H Käntiäinen, S Järvenpää, L Virta, T Pohjolainen, M Korpela, T Mötönen, K Puolakka
- 678** Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review
N ter Haar, H Lachmann, S Özen, P Woo, Y Uziel, C Modesto, I Koné-Paut, L Cantarini, A Insalaco, B Neven, M Hofer, D Rigante, S Al-Mayouf, I Touitou, R Gallizzi, E Papadopoulou-Alataki, S Martino, J Kuemmerle-Deschner, L Obici, N Lagaru, A Simon, S Nielsen, A Martini, N Ruperto, M Gattorno, J Frenkel, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Eurofever/Eurotraps Projects
- 686** The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
D Lazarevic, A Pistorio, E Palmisani, P Miettunen, A Ravelli, C Pilkington, N M Wulffraat, C Malattia, S M Garay, M Hofer, P Quartier, P Dolezalova, I C Penades, V P L Ferriani, G Ganser, O Kasapcopur, J A Melo-Gomes, A M Reed, M Wierzbowska, L G Rider, A Martini, N Ruperto; for the Paediatric Rheumatology International Trials Organisation (PRINTO)
- 694** Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study
G Trifirò, P Morabito, L Cavagna, C Ferrajolo, S Pecchioli, M Simonetti, E Bianchini, G Medea, C Cricelli, A P Caputi, G Mazzaglia
- 701** A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study
M A McAdams-DeMarco, J W Maynard, A N Baer, L W Kao, A Kottgen, J Coresh
- 707** Quantitative MRI measures of cartilage predict knee replacement: a case-control study from the Osteoarthritis Initiative
F Eckstein, C K Kwoh, R M Boudreau, Z Wang, M J Hannon, S Cotofana, M I Hudelmaier, W Wirth, A Guermazi, M C Nevitt, M R John, D J Hunter; for the OAI investigators
- 715** The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone
L Eder, J Jayakar, S Shanmugarajah, A Thavaneswaran, D Pereira, V Chandran, C F Rosen, D D Gladman
- 721** Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register
M H Oen, F H M Prince, J Anink, R ten Cate, E P A H Hoppenreijts, W Armborst, Y Koopman-Keemink, P A van Pelt, S Kamphuis, S L Gorter, K M Dolman, J F Swart, J M van den Berg, N M Wulffraat, M A J van Rossum, L W A van Suijlekom-Smit
- 728** Prevalence of interferon type I signature in CD14 monocytes of patients with Sjögren's syndrome and association with disease activity and BAFF gene expression
Z Brčić, N I Maria, C G van Helden-Meeuwssen, J P van de Merwe, P L van Daele, V A Dalm, M E Wildenberg, W Beumer, H A Drexhage, M A Versnel
- 736** High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires
M Haroon, B Kirby, O FitzGerald

MORE CONTENTS ►

EDITOR'S CHOICE

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



OPEN ACCESS

This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

www.publicationethics.org.uk



When you have finished with this please recycle it

741 Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial
R Westhovens, F De Keyser, D Rekalov, E L Nasonov, J Beetens, A Van der Aa, P Wigerinck, F Namour, F Vanhoutte, P Durez

745 Do the 2010 ACR/EULAR or ACR 1987 classification criteria predict erosive disease in early arthritis?
H Mäkinen, K Kaarela, H Huhtala, P J Hannonen, M Korpela, T Sokka

Basic and translational research

748 A novel disease-modifying osteoarthritis drug candidate targeting Runx1

F Yano, H Hojo, S Ohba, A Fukai, Y Hosaka, T Ikeda, T Saito, M Hirata, H Chikuda, T Takato, H Kawaguchi, Ung-il Chung

754 Simvastatin inhibits the pro-inflammatory and pro-thrombotic effects of IL-17 and TNF- α on endothelial cells
A Hot, F Lavocat, V Lenief, P Miossec

761 Autophagy regulates TNF α -mediated joint destruction in experimental arthritis
N-Y Lin, C Beyer, A Giebl, T Kireva, C Scholtysek, S Uderhardt, L E Munoz, C Dees, A Distler, S Wirtz, G Krönke, B Spencer, O Distler, G Schett, J H W Distler

769 Genetic studies on components of the Wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis
D P C de Rooy, N G Yerenko, A G Wilson, R Knevel, E Lindqvist, T Saxne, A Krabben, M K Leijmsma, N A Daha, S Tsunaka, A Zhemakova, J J Houwing-Duistermaat, T W J Huizinga, R E M Toes, D L P Baeten, E Brouwer, A H M van der Helm-van Mil

776 The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
J Lübbers, M Brink, L A van de Stadt, S Vosslander, J G Wesseling, D van Schaardenburg, S Rantapää-Dahlqvist, C L Verweij

Letters

782 Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome
F Ciccia, A Giardina, A Rizzo, G Guggino, P Cipriani, F Carubbi, R Giacomelli, G Triolo

783 Interleukin-1 receptor antagonist in refractory haemochromatosis-related arthritis of the hands
A Latourte, A Frazier, C Brière, H-K Ea, P Richette

785 Value of high-sensitivity C-reactive protein for classification of early axial spondyloarthritis: results from the DESIR cohort
V Navarro-Compán, D van der Heijde, B Combe, C Cosson, F A van Gaalen

786 Changing sulphasalazine to methotrexate does not improve the 2-year outcomes of the initial single DMARD treatment in early rheumatoid arthritis: subanalysis of the FIN-RACo trial
V M Ramalahti, H Kautiainen, M Korpela, P J Hannonen, M Leirisalo-Repo, T Möttönen, for the FIN-RACo Trial Group

Miscellaneous

788 Corrections

Electronic pages

e1 TNF antagonists and shingles: is vaccination advisable?
M K Nisar, A J K Ostor

e2 Comment on Predictors of preterm birth in patients with mild systemic lupus erythematosus by Clowse *et al*
R Rokutanda, M Kishimoto, G A Deshpande, K Yamaguchi, M Okada

e3 Are IL-10+ regulatory Th17 cells implicated in the sustained response to glucocorticoid treatment in patients with giant cell arteritis? Comment on the paper of Espigol-Frigole *et al*
M Samson, S Audia, N Janikashvili, B Bonnotte

e4 Herpes zoster infection risk in patients with rheumatoid arthritis on tumour necrosis factor inhibitors
P Ranganathan

e5 Gout: why is this curable disease so seldom cured?
S S Yeap, S C Gun

e6 Step-up therapy remains an appropriate option
D R Porter

e7 eLetter: Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors by M Genovese
A Triantafyllou, A Pырpasopoulou, P Anyfanti, E Balaska, S Aslanidis, S Douma

e8 Reply to: Forget personalized medicine and focus on abating disease activity
W S Wilke

e9 Comment on 'Associations between statin use and changes in pain, function and structural progression: a longitudinal study of persons with knee osteoarthritis'
S Clockaerts, G J V M Van Osch, S M Bierma-Zeinstra